{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:17:41Z","timestamp":1794961061623,"version":"4.9.1"},"reference-count":149,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The last decade has witnessed great advances in our understanding of the genetic and biological basis of childhood acute lymphoblastic leukemia (ALL), the development of experimental models to probe mechanisms and evaluate new therapies, and the development of more efficacious treatment stratification. Genomic analyses have revolutionized our understanding of the molecular taxonomy of ALL, and these advances have led the push to implement genome and transcriptome characterization in the clinical management of ALL to facilitate more accurate risk-stratification and, in some cases, targeted therapy. Although mutation- or pathway-directed targeted therapy (e.g., using tyrosine kinase inhibitors to treat Philadelphia chromosome [Ph]-positive and Phlike B-cell-ALL) is currently available for only a minority of children with ALL, many of the newly identified molecular alterations have led to the exploration of approaches targeting deregulated cell pathways. The efficacy of cellular or humoral immunotherapy has been demonstrated with the success of chimeric antigen receptor T-cell therapy and the bispecific engager blinatumomab in treating advanced disease. This review describes key advances in our understanding of the biology of ALL and optimal approaches to risk-stratification and therapy, and it suggests key areas for basic and clinical research.<\/jats:p>","DOI":"10.3324\/haematol.2020.247031","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:50:52Z","timestamp":1599724252000},"page":"2524-2539","source":"Crossref","is-referenced-by-count":589,"title":["Pediatric acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"105","author":[{"given":"Hiroto","family":"Inaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"13652","doi-asserted-by":"crossref","unstructured":"Moricke A, Zimmermann M, Valsecchi MG. Dexamethasone versus prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101-2112.","DOI":"10.1182\/blood-2015-09-670729"},{"key":"13653","doi-asserted-by":"crossref","unstructured":"Larsen EC, Devidas M, Chen S. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-2388.","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"13654","doi-asserted-by":"crossref","unstructured":"Maloney KW, Devidas M, Wang C. Outcome in children with standard-risk Bcell acute lymphoblastic leukemia: results of Children's Oncology Group Trial AALL0331. J Clin Oncol. 2020;38(6):602-612.","DOI":"10.1200\/JCO.19.01086"},{"key":"13655","doi-asserted-by":"crossref","unstructured":"Winter SS, Dunsmore KP, Devidas M. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018;36(29):2926-2934.","DOI":"10.1200\/JCO.2018.77.7250"},{"key":"13656","doi-asserted-by":"crossref","unstructured":"Place AE, Stevenson KE, Vrooman LM. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli Lasparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677-1690.","DOI":"10.1016\/S1470-2045(15)00363-0"},{"key":"13657","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591-2601.","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"13658","doi-asserted-by":"crossref","unstructured":"Vora A, Goulden N, Mitchell C. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15(8):809-818.","DOI":"10.1016\/S1470-2045(14)70243-8"},{"key":"13659","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606-615.","DOI":"10.1038\/leu.2017.265"},{"key":"13660","doi-asserted-by":"crossref","unstructured":"Jeha S, Pei D, Choi J. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377-3391.","DOI":"10.1200\/JCO.19.01692"},{"key":"13661","doi-asserted-by":"crossref","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242-252.","DOI":"10.1038\/ng.2532"},{"key":"13662","doi-asserted-by":"crossref","unstructured":"Moriyama T, Metzger ML, Wu G. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 2015;16(16):1659-1666.","DOI":"10.1016\/S1470-2045(15)00369-1"},{"key":"13663","doi-asserted-by":"crossref","unstructured":"Shah S, Schrader KA, Waanders E. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45(10):1226-1231.","DOI":"10.1038\/ng.2754"},{"key":"13664","doi-asserted-by":"crossref","unstructured":"Noetzli L, Lo RW, Lee-Sherick AB. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47(5):535-538.","DOI":"10.1038\/ng.3253"},{"key":"13665","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Goorha S, Radtke I. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.","DOI":"10.1038\/nature05690"},{"key":"13666","doi-asserted-by":"crossref","unstructured":"Gu Z, Churchman ML, Roberts KG. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296-307.","DOI":"10.1038\/s41588-018-0315-5"},{"key":"13667","doi-asserted-by":"crossref","unstructured":"Churchman ML, Qian M, Te Kronnie G. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33(5):937-948.","DOI":"10.1016\/j.ccell.2018.03.021"},{"key":"13668","doi-asserted-by":"crossref","unstructured":"Kuehn HS, Boisson B, Cunningham-Rundles C. Loss of B cells in patients with heterozygous mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043.","DOI":"10.1056\/NEJMoa1512234"},{"key":"13669","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Miller CB, Radtke I. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-114.","DOI":"10.1038\/nature06866"},{"key":"13670","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Su X, Zhang J. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.","DOI":"10.1056\/NEJMoa0808253"},{"key":"13671","doi-asserted-by":"crossref","unstructured":"Zhang J, McCastlain K, Yoshihara H. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48(12):1481-1489.","DOI":"10.1038\/ng.3691"},{"key":"13672","doi-asserted-by":"crossref","unstructured":"Brown AL, Arts P, Carmichael CL. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4(6):1131-1144.","DOI":"10.1182\/bloodadvances.2019000901"},{"key":"13673","doi-asserted-by":"crossref","unstructured":"Feurstein S, Godley LA. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017;106(2):189-195.","DOI":"10.1007\/s12185-017-2259-4"},{"key":"13674","doi-asserted-by":"crossref","unstructured":"Gocho Y, Yang JJ. Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia. Blood. 2019;134(10):793-797.","DOI":"10.1182\/blood.2018852400"},{"key":"13675","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Hosking FJ, Vijayakrishnan J. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006-1010.","DOI":"10.1038\/ng.430"},{"key":"13676","doi-asserted-by":"crossref","unstructured":"Trevino LR, Yang W, French D. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001-1005.","DOI":"10.1038\/ng.432"},{"key":"13677","doi-asserted-by":"crossref","unstructured":"Perez-Andreu V, Roberts KG, Harvey RC. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet. 2013;45(12):1494-1498.","DOI":"10.1038\/ng.2803"},{"key":"13678","doi-asserted-by":"crossref","unstructured":"Qian M, Xu H, Perez-Andreu V. Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood. 2019;133(7):724-729.","DOI":"10.1182\/blood-2018-07-862946"},{"key":"13679","doi-asserted-by":"crossref","unstructured":"Qian M, Zhao X, Devidas M. Genomewide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children. J Natl Cancer Inst. 2019;111(12):1350-1357.","DOI":"10.1093\/jnci\/djz043"},{"key":"13680","doi-asserted-by":"crossref","unstructured":"de Smith AJ, Lavoie G, Walsh KM. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2019;58(10):723-730.","DOI":"10.1002\/gcc.22765"},{"key":"13681","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221288"},{"key":"13682","doi-asserted-by":"crossref","unstructured":"Winer P, Muskens IS, Walsh KM. Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675.","DOI":"10.1182\/bloodadvances.2019001216"},{"key":"13683","unstructured":"Greaves M. Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol. 2003;7(3):233-245."},{"key":"13684","doi-asserted-by":"crossref","unstructured":"Greaves MF, Maia AT, Wiemels JL, Ford AM. Leukemia in twins: lessons in natural history. Blood. 2003;102(7):2321-2333.","DOI":"10.1182\/blood-2002-12-3817"},{"key":"13685","doi-asserted-by":"crossref","unstructured":"Ma Y, Dobbins SE, Sherborne AL. Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2013;110(18):7429-7433.","DOI":"10.1073\/pnas.1221099110"},{"key":"13686","doi-asserted-by":"crossref","unstructured":"Bueno C, Tejedor JR, Bashford-Rogers R. Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCPALL. Blood. 2019;134(11):900-905.","DOI":"10.1182\/blood.2019000893"},{"key":"13687","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034835"},{"key":"13688","doi-asserted-by":"crossref","unstructured":"Paulsson K, Lilljebjorn H, Biloglav A. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672-676.","DOI":"10.1038\/ng.3301"},{"key":"13689","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2019.07.009"},{"key":"13690","doi-asserted-by":"crossref","unstructured":"Moorman AV, Robinson H, Schwab C. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials. J Clin Oncol. 2013;31(27):3389-3396.","DOI":"10.1200\/JCO.2013.48.9377"},{"key":"13691","doi-asserted-by":"crossref","unstructured":"Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood. 1991;77(4):687-693.","DOI":"10.1182\/blood.V77.4.687.687"},{"key":"13692","doi-asserted-by":"crossref","unstructured":"Crist WM, Carroll AJ, Shuster JJ. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood. 1990;76(1):117-122.","DOI":"10.1182\/blood.V76.1.117.117"},{"key":"13693","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7228"},{"key":"13694","doi-asserted-by":"crossref","unstructured":"Lilljebjorn H, Henningsson R, Hyrenius-Wittsten A. Identification of ETV6- RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.","DOI":"10.1038\/ncomms11790"},{"key":"13695","doi-asserted-by":"crossref","unstructured":"Zaliova M, Kotrova M, Bresolin S. ETV6\/RUNX1-like acute lymphoblastic leukemia: a novel B-cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype. Genes Chromosomes Cancer. 2017;56(8):608-616.","DOI":"10.1002\/gcc.22464"},{"key":"13696","doi-asserted-by":"crossref","unstructured":"Yasuda T, Tsuzuki S, Kawazu M. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016;48(5):569-574.","DOI":"10.1038\/ng.3535"},{"key":"13697","doi-asserted-by":"crossref","unstructured":"Zaliova M, Stuchly J, Winkowska L. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica. 2019;104(7):1396-1406.","DOI":"10.3324\/haematol.2018.204974"},{"key":"13698","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814397115"},{"key":"13699","doi-asserted-by":"crossref","unstructured":"Alexander TB, Gu Z, Iacobucci I. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373-379.","DOI":"10.1038\/s41586-018-0436-0"},{"key":"13700","doi-asserted-by":"crossref","unstructured":"Griffith M, Griffith OL, Krysiak K. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol. 2016;44(7):603-613.","DOI":"10.1016\/j.exphem.2016.04.011"},{"key":"13701","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27265"},{"key":"13702","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13331"},{"key":"13703","doi-asserted-by":"crossref","unstructured":"Suzuki K, Okuno Y, Kawashima N. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol. 2016;34(28):3451-3459.","DOI":"10.1200\/JCO.2016.66.5547"},{"key":"13704","doi-asserted-by":"crossref","unstructured":"Ohki K, Kiyokawa N, Saito Y. Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2DHNRNPH1 gene fusion. Haematologica. 2019;104(1):128-137.","DOI":"10.3324\/haematol.2017.186320"},{"key":"13705","doi-asserted-by":"crossref","unstructured":"Schwab C, Nebral K, Chilton L. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? Blood Adv. 2017;1(19):1473-1477.","DOI":"10.1182\/bloodadvances.2017006734"},{"key":"13706","doi-asserted-by":"crossref","unstructured":"Passet M, Boissel N, Sigaux F. PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284.","DOI":"10.1182\/blood-2018-10-882142"},{"key":"13707","doi-asserted-by":"crossref","unstructured":"Churchman ML, Low J, Qu C. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell. 2015;28(3):343-356.","DOI":"10.1016\/j.ccell.2015.07.016"},{"key":"13708","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Vitale A, Cazzaniga G. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013;98(11):1702-1710.","DOI":"10.3324\/haematol.2012.080432"},{"key":"13709","doi-asserted-by":"crossref","unstructured":"Stanulla M, Dagdan E, Zaliova M. IKZF1(plus) Defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240-1249.","DOI":"10.1200\/JCO.2017.74.3617"},{"key":"13710","doi-asserted-by":"crossref","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"13711","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"13712","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035246"},{"key":"13713","doi-asserted-by":"crossref","unstructured":"Liu Y, Easton J, Shao Y. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1211-1218.","DOI":"10.1038\/ng.3909"},{"key":"13714","doi-asserted-by":"crossref","unstructured":"Mansour MR, Abraham BJ, Anders L. Oncogene regulation. An oncogenic superenhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014;346(6215):1373-1377.","DOI":"10.1126\/science.1259037"},{"key":"13715","doi-asserted-by":"crossref","unstructured":"Abraham BJ, Hnisz D, Weintraub AS. Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun. 2017;8:14385.","DOI":"10.1038\/ncomms14385"},{"key":"13716","doi-asserted-by":"crossref","unstructured":"Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011;208(13):2571-2579.","DOI":"10.1084\/jem.20112239"},{"key":"13717","doi-asserted-by":"crossref","unstructured":"Della Gatta G, Palomero T, Perez-Garcia A. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med. 2012;18(3):436-440.","DOI":"10.1038\/nm.2610"},{"key":"13718","doi-asserted-by":"crossref","unstructured":"Zhang J, Ding L, Holmfeldt L. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.","DOI":"10.1038\/nature10725"},{"key":"13719","doi-asserted-by":"crossref","unstructured":"Yui MA, Rothenberg EV. Developmental gene networks: a triathlon on the course to T cell identity. Nat Rev Immunol. 2014;14(8):529-545.","DOI":"10.1038\/nri3702"},{"key":"13720","doi-asserted-by":"crossref","unstructured":"Weng AP, Ferrando AA, Lee W. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.","DOI":"10.1126\/science.1102160"},{"key":"13721","doi-asserted-by":"crossref","unstructured":"Palomero T, Lim WK, Odom DT. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261-18266.","DOI":"10.1073\/pnas.0606108103"},{"key":"13722","doi-asserted-by":"crossref","unstructured":"Herranz D, Ambesi-Impiombato A, Palomero T. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med. 2014;20(10):1130-1137.","DOI":"10.1038\/nm.3665"},{"key":"13723","doi-asserted-by":"crossref","unstructured":"Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84(12):4038-4044.","DOI":"10.1182\/blood.V84.12.4038.bloodjournal84124038"},{"key":"13724","doi-asserted-by":"crossref","unstructured":"Palomero T, Sulis ML, Cortina M. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210.","DOI":"10.1038\/nm1636"},{"key":"13725","doi-asserted-by":"crossref","unstructured":"Zenatti PP, Ribeiro D, Li W. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011;43(10):932-939.","DOI":"10.1038\/ng.924"},{"key":"13726","doi-asserted-by":"crossref","unstructured":"Kontro M, Kuusanmaki H, Eldfors S. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 2014;28(8):1738-1742.","DOI":"10.1038\/leu.2014.89"},{"key":"13727","doi-asserted-by":"crossref","unstructured":"Graux C, Stevens-Kroef M, Lafage M. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia. 2009;23(1):125-133.","DOI":"10.1038\/leu.2008.278"},{"key":"13728","doi-asserted-by":"crossref","unstructured":"Anderson K, Lutz C, van Delft FW. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356-361.","DOI":"10.1038\/nature09650"},{"key":"13729","doi-asserted-by":"crossref","unstructured":"De Bie J, Demeyer S, Alberti-Servera L. Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia. Leukemia. 2018;32(6):1358-1369.","DOI":"10.1038\/s41375-018-0127-8"},{"key":"13730","doi-asserted-by":"crossref","unstructured":"Ma X, Edmonson M, Yergeau D. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.","DOI":"10.1038\/ncomms7604"},{"key":"13731","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Zhang J, Kasper LH. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471(7337):235-239.","DOI":"10.1038\/nature09727"},{"key":"13732","doi-asserted-by":"crossref","unstructured":"Li B, Brady SW, Ma X. Therapyinduced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1):41-55.","DOI":"10.1182\/blood.2019002220"},{"key":"13733","doi-asserted-by":"crossref","unstructured":"Mar BG, Bullinger LB, McLean KM. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014;5:3469.","DOI":"10.1038\/ncomms4469"},{"key":"13734","doi-asserted-by":"crossref","unstructured":"Waanders E, Gu Z, Dobson SM. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Disc. 2020;1(1):96-111.","DOI":"10.1158\/0008-5472.BCD-19-0041"},{"key":"13735","doi-asserted-by":"crossref","unstructured":"Dobson SM, Garcia-Prat L, Vanner RJ. Relapse-fated latent diagnosis subclones in acute B lineage leukemia are drug tolerant and possess distinct metabolic programs. Cancer Disc. 2020;10(4):568-587.","DOI":"10.1158\/2159-8290.CD-19-1059"},{"key":"13736","doi-asserted-by":"crossref","unstructured":"Li B, Li H, Bai Y. Negative feedbackdefective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015;21(6):563-571.","DOI":"10.1038\/nm.3840"},{"key":"13737","doi-asserted-by":"crossref","unstructured":"Meyer JA, Wang J, Hogan LE. Relapsespecific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45(3):290-294.","DOI":"10.1038\/ng.2558"},{"key":"13738","doi-asserted-by":"crossref","unstructured":"Yang JJ, Cheng C, Devidas M. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet. 2011;43(3):237-241.","DOI":"10.1038\/ng.763"},{"key":"13739","doi-asserted-by":"crossref","unstructured":"Yang JJ, Landier W, Yang W. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33(11):1235-1242.","DOI":"10.1200\/JCO.2014.59.4671"},{"key":"13740","doi-asserted-by":"crossref","unstructured":"Karol SE, Larsen E, Cheng C. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia. 2017;31(6):1325-1332.","DOI":"10.1038\/leu.2017.24"},{"key":"13741","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"13742","doi-asserted-by":"crossref","unstructured":"Hrusak O, de Haas V, Stancikova J. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018;132(3):264-276.","DOI":"10.1182\/blood-2017-12-821363"},{"key":"13743","doi-asserted-by":"crossref","unstructured":"Fischer U, Forster M, Rinaldi A. Genomics and drug profiling of fatal TCF3- HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47(9):1020-1029.","DOI":"10.1038\/ng.3362"},{"key":"13744","doi-asserted-by":"crossref","unstructured":"Pui CH, Pei D, Raimondi SC. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response- Adapted therapy. Leukemia. 2017;31(2):333-339.","DOI":"10.1038\/leu.2016.234"},{"key":"13745","doi-asserted-by":"crossref","unstructured":"O'Connor D, Enshaei A, Bartram J. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36(1):34-43.","DOI":"10.1200\/JCO.2017.74.0449"},{"key":"13746","doi-asserted-by":"crossref","unstructured":"Wood B, Wu D, Crossley B. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131(12):1350-1359.","DOI":"10.1182\/blood-2017-09-806521"},{"key":"13747","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30050-X"},{"key":"13748","doi-asserted-by":"crossref","unstructured":"Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096-1106.","DOI":"10.1016\/S1470-2045(10)70114-5"},{"key":"13749","doi-asserted-by":"crossref","unstructured":"Wolf J, Tang L, Flynn PM. Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia. Clin Infect Dis. 2017;65(11):1790-1798.","DOI":"10.1093\/cid\/cix644"},{"key":"13750","doi-asserted-by":"crossref","unstructured":"Alexander S, Fisher BT, Gaur AH. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995-1004.","DOI":"10.1001\/jama.2018.12512"},{"key":"13751","doi-asserted-by":"crossref","unstructured":"Mattano LA Jr, Devidas M, Nachman JB. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906-915.","DOI":"10.1016\/S1470-2045(12)70274-7"},{"key":"13752","doi-asserted-by":"crossref","unstructured":"Warris LT, van den Heuvel-Eibrink MM, Aarsen FK. Hydrocortisone as an intervention for dexamethasone-induced adverse effects in pediatric patients with acute lymphoblastic leukemia: results of a doubleblind, randomized controlled trial. J Clin Oncol. 2016;34(19):2287-2293.","DOI":"10.1200\/JCO.2015.66.0761"},{"key":"13753","doi-asserted-by":"crossref","unstructured":"Diouf B, Crews KR, Lew G. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815-823.","DOI":"10.1001\/jama.2015.0894"},{"key":"13754","doi-asserted-by":"crossref","unstructured":"Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715-724.","DOI":"10.1200\/JCO.19.02292"},{"key":"13755","doi-asserted-by":"crossref","unstructured":"Albertsen BK, Grell K, Abrahamsson J. Intermittent versus continuous PEGasparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019;37(19):1638-1646.","DOI":"10.1200\/JCO.18.01877"},{"key":"13756","doi-asserted-by":"crossref","unstructured":"Liu Y, Smith CA, Panetta JC. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051-2061.","DOI":"10.1200\/JCO.18.02439"},{"key":"13757","doi-asserted-by":"crossref","unstructured":"Maury S, Chevret S, Thomas X. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044-1053.","DOI":"10.1056\/NEJMoa1605085"},{"key":"13758","doi-asserted-by":"crossref","unstructured":"Gupta S, Wang C, Raetz EA. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38(17):1897-1905.","DOI":"10.1200\/JCO.19.03024"},{"key":"13759","doi-asserted-by":"crossref","unstructured":"Salzer WL, Asselin B, Supko JG. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood. 2013;122(4):507-514.","DOI":"10.1182\/blood-2013-01-480822"},{"key":"13760","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27797"},{"key":"13761","doi-asserted-by":"crossref","unstructured":"Swanson HD, Panetta JC, Barker PJ. Predicting success of desensitization after pegaspargase allergy. Blood. 2020;135(1):71-75.","DOI":"10.1182\/blood.2019003407"},{"key":"13762","doi-asserted-by":"crossref","unstructured":"Conter V, Bartram CR, Valsecchi MG. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.","DOI":"10.1182\/blood-2009-10-248146"},{"key":"13763","doi-asserted-by":"crossref","unstructured":"Schrappe M, Valsecchi MG, Bartram CR. Late MRD response determines relapse risk overall and in subsets of childhood Tcell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077-2084.","DOI":"10.1182\/blood-2011-03-338707"},{"key":"13764","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00254-9"},{"key":"13765","doi-asserted-by":"crossref","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580-588.","DOI":"10.1182\/asheducation-2016.1.580"},{"key":"13766","unstructured":"Dunsmore KP, Winter SS, Devidas M. Children's Oncology Group AALL0434: A phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020 Aug 19 [Epub ahead of print]."},{"key":"13767","doi-asserted-by":"crossref","unstructured":"Schrappe M, Bleckmann K, Zimmermann M. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOPBFM ALL 2000). J Clin Oncol. 2018;36(3):244-253.","DOI":"10.1200\/JCO.2017.74.4946"},{"key":"13768","doi-asserted-by":"crossref","unstructured":"Kato M, Ishimaru S, Seki M. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2017;31(3):580-584.","DOI":"10.1038\/leu.2016.274"},{"key":"13769","doi-asserted-by":"crossref","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 update. Clin Pharmacol Ther. 2019;105(5):1095-1105.","DOI":"10.1002\/cpt.1304"},{"key":"13770","doi-asserted-by":"crossref","unstructured":"Bhatia S, Landier W, Hageman L. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children's Oncology Group Study. JAMA Oncol. 2015;1(3):287-295.","DOI":"10.1001\/jamaoncol.2015.0245"},{"key":"13771","doi-asserted-by":"crossref","unstructured":"Landier W, Hageman L, Chen Y. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group Study AALL03N1. J Clin Oncol. 2017;35(15):1730-1736.","DOI":"10.1200\/JCO.2016.71.7579"},{"key":"13772","doi-asserted-by":"crossref","unstructured":"Vora A, Andreano A, Pui CH. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34(9):919-926.","DOI":"10.1200\/JCO.2015.64.2850"},{"key":"13773","doi-asserted-by":"crossref","unstructured":"Winick N, Devidas M, Chen S. Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2017;35(22):2527-2534.","DOI":"10.1200\/JCO.2016.71.4774"},{"key":"13774","doi-asserted-by":"crossref","unstructured":"Liu HC, Yeh TC, Hou JY. Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. J Clin Oncol. 2014;32(17):1825-1829.","DOI":"10.1200\/JCO.2013.54.5020"},{"key":"13775","doi-asserted-by":"crossref","unstructured":"Thastrup M, Marquart HV, Levinsen M. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia. 2020;34(2):336-346.","DOI":"10.1038\/s41375-019-0570-1"},{"key":"13776","doi-asserted-by":"crossref","unstructured":"Gabelli M, Disaro S, Scarparo P. Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2825-2828.","DOI":"10.1080\/10428194.2019.1602269"},{"key":"13777","doi-asserted-by":"crossref","unstructured":"Schultz KR, Carroll A, Heerema NA. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-1471.","DOI":"10.1038\/leu.2014.30"},{"key":"13778","doi-asserted-by":"crossref","unstructured":"Shen S, Chen X, Cai J. Effect of dasatinib versus imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358-366.","DOI":"10.1001\/jamaoncol.2019.5868"},{"key":"13779","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Ravandi F. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547-1555.","DOI":"10.1016\/S1470-2045(15)00207-7"},{"key":"13780","doi-asserted-by":"crossref","unstructured":"Roberts KG, Li Y, Payne-Turner D. Targetable kinase-activating lesions in Phlike acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-1015.","DOI":"10.1056\/NEJMoa1403088"},{"key":"13781","doi-asserted-by":"crossref","unstructured":"Tanasi I, Ba I, Sirvent N. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABLclass rearrangements. Blood. 2019;134(16):1351-1355.","DOI":"10.1182\/blood.2019001244"},{"key":"13782","doi-asserted-by":"crossref","unstructured":"Seyfried F, Demir S, Horl RL. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019;10(8):571.","DOI":"10.1038\/s41419-019-1801-0"},{"key":"13783","doi-asserted-by":"crossref","unstructured":"Khaw SL, Suryani S, Evans K. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLLrearranged leukemia. Blood. 2016;128(10):1382-1395.","DOI":"10.1182\/blood-2016-03-707414"},{"key":"13784","doi-asserted-by":"crossref","unstructured":"Diaz-Flores E, Comeaux EQ, Kim KL. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79(9):2339-2351.","DOI":"10.1158\/0008-5472.CAN-18-0236"},{"key":"13785","doi-asserted-by":"crossref","unstructured":"Messinger YH, Gaynon PS, Sposto R. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia &#x0026; Lymphoma (TACL) Study. Blood. 2012;120(2):285-290.","DOI":"10.1182\/blood-2012-04-418640"},{"key":"13786","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27062"},{"key":"13787","doi-asserted-by":"crossref","unstructured":"Brown P, Pieters R, Biondi A. How I treat infant leukemia. Blood. 2019;133(3):205-214.","DOI":"10.1182\/blood-2018-04-785980"},{"key":"13788","doi-asserted-by":"crossref","unstructured":"Inaba H, Pui CH. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev. 2019;38(4):595-610.","DOI":"10.1007\/s10555-019-09834-0"},{"key":"13789","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, Gokbuget N. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.","DOI":"10.1056\/NEJMoa1609783"},{"key":"13790","doi-asserted-by":"crossref","unstructured":"Gokbuget N, Dombret H, Bonifacio M. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"13791","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132435"},{"key":"13792","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.","DOI":"10.1056\/NEJMoa1509277"},{"key":"13793","doi-asserted-by":"crossref","unstructured":"Bhojwani D, Sposto R, Shah NN. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33(4):884-892.","DOI":"10.1038\/s41375-018-0265-z"},{"key":"13794","doi-asserted-by":"crossref","unstructured":"Jabbour E, Ravandi F, Kebriaei P. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230-234.","DOI":"10.1001\/jamaoncol.2017.2380"},{"key":"13795","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"13796","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.","DOI":"10.1056\/NEJMoa1407222"},{"key":"13797","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-385."},{"key":"13798","doi-asserted-by":"crossref","unstructured":"Gardner RA, Ceppi F, Rivers J. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019;134(24):2149-2158.","DOI":"10.1182\/blood.2019001463"},{"key":"13799","doi-asserted-by":"crossref","unstructured":"Zhang X, Lu XA, Yang J. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325-2338.","DOI":"10.1182\/bloodadvances.2020001466"},{"key":"13800","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738070"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.247031\/72388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.247031\/72526","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10004\/72388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:58:06Z","timestamp":1794045486000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2020.247031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":149,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.247031","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}